Heme-Oxygenase 1 Mediated Activation of Cyp3A11 Protects Against Non-Steroidal Pain Analgesics Induced Acute Liver Damage in Sickle Cell Disease Mice
Cells · 2025
DOI: 10.3390/cells14030194 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Ravi Vats und 4 weiteren Autor:innen. Beteiligte Einrichtung: Versiti Blood Research Institute and Blood Center of Wisconsin, 8733 West Watertown Plank Road, Milwaukee, WI 53226, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Heme Oxygenase-1, Cytochrome P-450 CYP3A, Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, the American Society of Hematology junior faculty scholar award.
Abstract (Originalsprache)
Pain constitutes a significant comorbidity associated with sickle cell disease (SCD). Analgesics serve as the primary method for pain management; however, the long-term effects of these drugs on the liver of SCD patients remain not completely understood. Using real-time intravital imaging, we analyzed the effect of non-steroidal analgesics (NSA) in the liver of control and SS (SCD) mice. Remarkably, we found completely opposing effects in the liver of control and SS mice post-NSA treatment. Whereas SS mice were able to better tolerate the NSA treatment acutely compared to their littermate controls, in the long term, these mice showed delayed resolution of liver injury and exacerbated fibrosis compared to control mice. Mechanistically, we found that SS mice were protected from cytotoxicity caused by NSA at baseline due to the significant activation of hepatic Kupffer cells, which produced heme-oxygenase 1 (HO-1). HO-1 promoted the activation of the cytoprotective enzyme Cyp3A11, which inhibited hepatic damage caused by NSA. However, in the long term, depletion of hepatic Kupffer cells led to reduced expression of HO-1, which blocked the activation of Cyp3A11, resulting in fibrosis and a delay in the resolution of liver injury and inflammation. These preclinical data provide a strong proof-of-concept for HO-1 as well as Cyp3A11 as cytoprotectors against NSA-induced liver damage in the Townes model of SCD and support further development of these compounds as potential novel therapies for end-organ damage in SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Versiti Blood Research Institute and Blood Center of Wisconsin, 8733 West Watertown Plank Road, Milwaukee, WI 53226, USA.
- Divisions of Cell Biology, Neurobiology and Anatomy and Bioengineering, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
ORCID-Profile: Ravi Vats, Rikesh K Dubey
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- the American Society of Hematology junior faculty scholar award
- Versiti start-up fund
- National Heart, Lung, and Blood Institute Grants
- the American Heart Association Grants
Zitieren
APA
Vats, R., Ungalara, R., Dubey, R. K., Sundd, P., & Pradhan-Sundd, T. (2025). Heme-Oxygenase 1 Mediated Activation of Cyp3A11 Protects Against Non-Steroidal Pain Analgesics Induced Acute Liver Damage in Sickle Cell Disease Mice. Cells. https://doi.org/10.3390/cells14030194
Vancouver
Vats R, Ungalara R, Dubey RK, Sundd P, Pradhan-Sundd T. Heme-Oxygenase 1 Mediated Activation of Cyp3A11 Protects Against Non-Steroidal Pain Analgesics Induced Acute Liver Damage in Sickle Cell Disease Mice. Cells. 2025. doi:10.3390/cells14030194
BibTeX
@article{Vats2025,
author = {Vats, Ravi and Ungalara, Ramakrishna and Dubey, Rikesh K and Sundd, Prithu and Pradhan-Sundd, Tirthadipa},
title = {Heme-Oxygenase 1 Mediated Activation of Cyp3A11 Protects Against Non-Steroidal Pain Analgesics Induced Acute Liver Damage in Sickle Cell Disease Mice},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14030194}
}
EUVIMED